Mesoblast (ASX:MSB; Nasdaq:MESO) Sets Stage for R&D Day as Ryoncil® Gains Commercial Traction

Highlights

• Mesoblast has scheduled its inaugural R&D Day on 8 April 2026 in New York City.
• The company reported H1 FY2026 revenue of US$51.3 million, driven by Ryoncil® launch.
• Ryoncil® achieved gross sales of US$57.0 million following U.S. commercial rollout.
• Phase 3 protocol for adult SR-aGvHD treatment finalised after FDA engagement.
• FY2026 Ryoncil® net revenue guidance projected between US$110 million and US$120 million.

In hospital settings where complications can escalate rapidly, treatment decisions for critically ill patients carry significant weight. For those undergoing stem cell transplants, conditions such as steroid-refractory acute graft-versus-host disease (SR-aGvHD) remain a major clinical challenge despite existing therapies. Within this context, Mesoblast Limited (ASX:MSB) (Nasdaq:MESO), an Australian developer of allogeneic cellular medicines for inflammatory diseases, is advancing its commercial and clinical strategy, with its cell therapy Ryoncil®, while new development pathways take shape.

Ryoncil® is the first FDA-approved, off the-shelf cell therapy for children aged 2 months and older, including adolescents and teenagers, with SRaGvHD, a life-threatening condition with high mortality rate.

SR-AGVHD presents a significant barrier to successful outcomes following allogeneic hematopoietic cell transplantation (HCT), despite advancements in GVHD prophylaxis and management.

As the company prepares to unveil its roadmap at an upcoming R&D Day in New York City, attention is turning to how its pipeline, technology platform, and expanding indications could shape the next phase of its growth.

The R&D event, scheduled to run from 8:00am to 11:00am EST and webcast live, will feature presentations from senior leadership and key opinion leaders, outlining corporate strategy, pipeline progress, and future development priorities.

R&D Day Focus

Mesoblast will use its inaugural R&D Day to outline its corporate strategy and pipeline direction. The event will include discussions on the commercialization of its lead product Ryoncil®, and its broader opportunities in inflammatory pain and cardiovascular disease. The company also plans to introduce new technology aimed at advancing the next phase of cellular medicine innovation.

According to Chief Executive Dr. Silviu Itescu, the event will highlight near-term and long-term growth drivers alongside key upcoming milestones across its pipeline.

Commercial Progress with Ryoncil®

The company’s financial performance in H1 FY2026 reflects the commercial launch of Ryoncil® (remestemcel-L-rknd).

FY2026 Outlook: Mesoblast has provided FY2026 net revenue guidance for Ryoncil® in the range of US$110 million to US$120 million, reflecting expectations for continued uptake following its commercial launch.

Pipeline Expansion Strategy

Mesoblast is progressing plans to extend the lifecycle of Ryoncil® into additional indications across both adult and children with inflammatory conditions. The Phase 3 trial protocol for its use in adult SR-aGvHD has been finalised following discussions with the FDA and is set for Institutional Review Board submission and site initiation.

The adult SR-aGvHD population is estimated to be approximately three times larger than the pediatric segment currently addressed.

Advancing Next-Generation Therapies

The company is also developing rexlemestrocel-L, its second-generation product, targeting chronic discogenic low back pain and inflammatory chronic heart failure with low ejection fraction. Mesoblast intends to leverage data from existing large randomized controlled trials to support regulatory approvals, aligning with updated FDA guidance that allows a single pivotal trial as a standard pathway.

These programs are expected to support multiple revenue streams across large-scale indications.

Technology and Platform Overview

Mesoblast develops allogeneic, off-the-shelf cellular medicines using its proprietary mesenchymal lineage cell technology platform. These therapies are designed to address severe inflammation by releasing anti-inflammatory factors that modulate immune system responses.

The company maintains a global intellectual property portfolio with over 1,000 granted patents or patent applications, providing protection across major markets through at least 2044. Its manufacturing capabilities support industrial-scale production of cryopreserved cellular therapies intended for global distribution.

Mesoblast operates across Australia, the United States, and Singapore, with commercial partnerships in Japan, Europe, and China.

Shares of MSB traded at AUD 2.09, at the time of writing on 27 March 2026.